Equillium
- Founded: 2017
- Location: La Jolla, CA
- Employee range: 11 - 50
- Clinical stage: Clin3 (fast track)
- Therapy area: GvHD (ODD)
- Drug types: IMM, X_X, NPH, DRM, GI
- Lead product: EQ001 (partners: Omo Pharmaceuticals, Biocon)
- Product link: https://www.equilliumbio.com/clinical/
- Funding: $30M stock Feb 2021; $35M stock Aug 2020; $65M IPO
equilliumbio.comhome/default.aspx linkedin.com job board
Short description:
Monoclonal Antibody Therapies
Drug notes:
Also Clin1b (Fast track) SLE/lupus nephritis; EQ101 Clin2 alopecia (ODD); EQ102 Clin1 celiac disease; undisclosed RD/Clin0 immunology & inflammatory disorders
Long description:
Equillium is using advances in immunobiology to create therapeutics to treat autoimmune diseases. A healthy immune system needs to be correctly balanced to ensure it is activated only against pathogenic or cancerous cells. To find effective therapeutics to restore balance, Equillium is using their multi-cytokine inhibitor platform to find peptides that use a novel modality to selectively inhibit multiple disease-driving cytokines, while leaving other immune regulatory pathways intact. Equillium’s lead candidate, Itolizumab, is an immune-modifying monoclonal antibody that downregulates pathogenic T effector cells and is being evaluated for multiple severe immune-inflammatory diseases.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com